Documentos relacionados

1. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
2. Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy.
3. Deep remission in Crohn's disease: is it the end of the placebo effect?
4. Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.
5. Trough Concentration Response in Infliximab and Adalimumab Treated Children With Inflammatory Bowel Disease Following Treatment Adjustment: A Pharmacokinetic Model.
6. Predictive parameters for the clinical course of Crohn's disease: development of a simple and reliable risk model.
7. Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease.
8. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
9. Epigenetic reader SP140 loss of function drives Crohn's disease due to uncontrolled macrophage topoisomerases.
10. Microgranulomas at Diagnosis Are Associated With Need for Antitumor Necrosis Factor Escalation in Pediatric Crohn Disease.